Immatics (IMTX) Current Deferred Revenue (2019 - 2025)
Immatics' (IMTX) quarterly Current Deferred Revenue came in at $21.6 million in Q4 2025, down 43.75% year-on-year from $38.4 million in Q4 2024, and down 27.78% quarter-over-quarter from $29.9 million in Q3 2025.
Immatics (IMTX) Current Deferred Revenue (2019 - 2025) Analysis & Trends
Immatics has disclosed Current Deferred Revenue across 7 years of filings, most recently posting $21.6 million for Q4 2025.
- Current Deferred Revenue for Q4 2025 came in at $21.6 million, down 43.75% year-over-year; the trailing twelve-month figure through Dec 2025 was $21.6 million (down 43.75% YoY), and the FY2025 annual result was $20.9 million, down 45.41% from the prior year.
- Current Deferred Revenue came in at $21.6 million for Q4 2025 at Immatics, down from $29.9 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $124.3 million in Q4 2023 to a low of $21.6 million in Q4 2025.
- The 5-year median for Current Deferred Revenue is $73.5 million (2021), against an average of $71.6 million.
- Across the five-year window, Current Deferred Revenue jumped 87.56% in 2023 and slumped 70.74% in 2025, its largest moves.
- Immatics' Current Deferred Revenue stood at $57.7 million in 2021, then advanced by 14.94% to $66.3 million in 2022, then surged by 87.56% to $124.3 million in 2023, then slumped by 69.13% to $38.4 million in 2024, then slumped by 43.75% to $21.6 million in 2025.
- The last three Current Deferred Revenue figures came in at $21.6 million (Q4 2025), $29.9 million (Q3 2025), and $31.2 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Immatics | 14.67 Bn | 14.67 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 21.58 Mn |
| Sep 30, 2025 | 29.88 Mn |
| Jun 30, 2025 | 31.20 Mn |
| Mar 31, 2025 | 30.68 Mn |
| Dec 31, 2024 | 38.37 Mn |
| Sep 30, 2024 | 75.70 Mn |
| Jun 30, 2024 | 102.87 Mn |
| Mar 31, 2024 | 104.86 Mn |
| Dec 31, 2023 | 124.30 Mn |
| Sep 30, 2023 | 67.55 Mn |
| Jun 30, 2023 | 74.04 Mn |
| Mar 31, 2023 | 70.07 Mn |
| Dec 31, 2022 | 66.27 Mn |
| Sep 30, 2022 | 104.07 Mn |
| Jun 30, 2022 | 123.05 Mn |
| Mar 31, 2022 | 76.08 Mn |
| Dec 31, 2021 | 57.66 Mn |
| Sep 30, 2021 | 72.97 Mn |
| Jun 30, 2021 | 74.91 Mn |
| Mar 31, 2021 | 86.50 Mn |